GlassScriptPhysician profile
Jennifer N Jensen
NPI 1790186955
$5,159.38
in general payments reported to CMS, 2019-2025
23 companies · $512 in 2025
The $512 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,227 · 2022: $1,275 · 2023: $828 · 2024: $317 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.91 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $773.96 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $753.13 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $687.44 | 2021-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $592.09 | 2021-2024 | |
| Abbott Laboratories | $442.64 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Heartflow, INC. | $259.25 | 2024-2025 | |
| Pfizer INC. | $245.99 | 2021 | |
| Amarin Pharma, INC. | $229.35 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.76 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $177.80 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $177.74 | 2022-2023 | Optimizer |
| Novo Nordisk INC | $126.48 | 2021-2024 | Wegovy |
| Boston Scientific Corporation | $103.92 | 2021-2025 | Watchman Flx, Ingevity Mri |
| Esperion Therapeutics, INC. | $102.91 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $88.36 | 2021-2023 | Opsumit, Uptravi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $42.97 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $36.32 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.78 | 2025 | Onpattro |
| Amgen INC. | $18.17 | 2021 | |
| Scpharmaceuticals INC. | $16.53 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.29 | 2023 | Gattex |
| Medicomp INC | $15.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.